These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30010807)

  • 1. Cardiac resynchronization is pro-arrhythmic in the absence of reverse ventricular remodelling: a systematic review and meta-analysis.
    Deif B; Ballantyne B; Almehmadi F; Mikhail M; McIntyre WF; Manlucu J; Yee R; Sapp JL; Roberts JD; Healey JS; Leong-Sit P; Tang AS
    Cardiovasc Res; 2018 Sep; 114(11):1435-1444. PubMed ID: 30010807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes.
    Sardu C; Barbieri M; Santamaria M; Giordano V; Sacra C; Paolisso P; Spirito A; Marfella R; Paolisso G; Rizzo MR
    Cardiovasc Diabetol; 2017 Jun; 16(1):75. PubMed ID: 28599667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular electrical delay as a predictor of arrhythmias in patients with cardiac resynchronization implantable cardioverter defibrillator.
    Elsaid O; Gulati V; Tecson K; Friedman M; Kluger J
    Scand Cardiovasc J; 2018 Dec; 52(6):356-361. PubMed ID: 30570402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced long-term overall mortality in heart failure patients with prolonged QRS treated with CRT combined with ICD vs. heart failure patients with narrow QRS treated with ICD only.
    Palmisano P; Accogli M; Pisanò EC; Zaccaria M; De Blasi S; Ponzetta MA; Valsecchi S; Milanese G; Lauretti M; Magliari F
    Europace; 2016 Sep; 18(9):1374-82. PubMed ID: 26612878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amiodarone is associated with adverse outcomes in patients with sustained ventricular arrhythmias upgraded to cardiac resynchronization therapy-defibrillators.
    Adelstein EC; Althouse AD; Davis L; Schwartzman D; Bazaz R; Jain S; Wang N; Saba S
    J Cardiovasc Electrophysiol; 2019 Mar; 30(3):348-356. PubMed ID: 30575185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular dimensions predict risk of appropriate shocks but not mortality in cardiac resynchronization therapy-defibrillator recipients with left bundle-branch block and non-ischemic cardiomyopathy.
    Adelstein EC; Schwartzman D; Jain S; Bazaz R; Wang NC; Saba S
    Europace; 2017 Oct; 19(10):1689-1694. PubMed ID: 27856539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study.
    Gunten SV; Theuns DA; Kühne M; Reichlin T; Sticherling C; Schaer B
    Cardiol J; 2019; 26(6):711-716. PubMed ID: 30484267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis.
    Barra S; Duehmke R; Providencia R; Marijon E; Boveda S; Virdee M; Heck P; Fynn S; Begley D; Grace A; Agarwal S
    Europace; 2018 Jan; 20(1):89-96. PubMed ID: 28031276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.
    Barra S; Providência R; Tang A; Heck P; Virdee M; Agarwal S
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26546574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMR DENSE and the Seattle Heart Failure Model Inform Survival and Arrhythmia Risk After CRT.
    Bilchick KC; Auger DA; Abdishektaei M; Mathew R; Sohn MW; Cai X; Sun C; Narayan A; Malhotra R; Darby A; Mangrum JM; Mehta N; Ferguson J; Mazimba S; Mason PK; Kramer CM; Levy WC; Epstein FH
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):924-936. PubMed ID: 31864974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
    Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
    Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy.
    Killu AM; Mazo A; Grupper A; Madhavan M; Webster T; Brooke KL; Hodge DO; Asirvatham SJ; Friedman PA; Glikson M; Cha YM
    Europace; 2018 Aug; 20(8):1303-1311. PubMed ID: 29016821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of ventricular arrhythmia in cardiac resynchronization therapy responders and super-responders: a systematic review and meta-analysis.
    Yuyun MF; Erqou SA; Peralta AO; Hoffmeister PS; Yarmohammadi H; Echouffo Tcheugui JB; Martin DT; Joseph J; Singh JP
    Europace; 2021 Aug; 23(8):1262-1274. PubMed ID: 33496319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT.
    Perkiomaki JS; Ruwald AC; Kutyifa V; Ruwald MH; Mcnitt S; Polonsky B; Goldstein RE; Haigney MC; Krone RJ; Zareba W; Moss AJ;
    Europace; 2015 Dec; 17(12):1816-22. PubMed ID: 26071234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients.
    Chen S; Ling Z; Kiuchi MG; Yin Y; Krucoff MW
    Europace; 2013 Jul; 15(7):992-1001. PubMed ID: 23419662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.